HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Store-brand acne cream recalled

This article was originally published in The Rose Sheet

Executive Summary

CSI, USA, Inc. voluntarily recalls all lots of 1-oz. tubes of its 10 percent benzoyl peroxide store-brand acne cream after samples of the products were found to contain bacteria identified as burkholderia cepacia. The Gallatin, Tenn.-based manufacturer Nov. 13 says the recall affects the following brands and retailers: DG Maximum Strength Acne Medicated Gel sold at Dollar General stores; Kroger Acne Gel 10% Benzoyl Peroxide Acne Medication sold at Kroger; and Equate Medicated Acne Gel sold at Wal-Mart. The company says the risk of illness to "healthy individuals" following use of the product is "very low," but there could be an increased health risk of infections for individuals with cuts, scrapes, rashes or other compromised skin conditions, or for people with weakened or suppressed immune systems

You may also be interested in...

Pandemic Response In US Consumer Health Market: OTC Pain Relief And Cough/Cold Purchases

Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.

venBio Raises $394m To Fund Biopharmas Through Human Proof-Of-Concept

Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.

FDA Wants To Put Hep C Tests On 510(k) Pathway

The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts